|
Guselkumab Clinical Trials
8 actively recruiting trials across 6 locations
Also known as: CNTO1959, TREMFYA, Tremfya
Pipeline
Phase 3: 2Phase 4: 4
Top Sponsors
- University of California, San Diego2
- Janssen Research & Development, LLC2
- University of Pennsylvania1
- NYU Langone Health1
- Johnson & Johnson Private Limited1
Indications
- Arthritis8
- Psoriatic Arthritis3
- Arthritis, Psoriatic3
- Psoriasis2
- Crohns Disease1
Other2 trials
Avondale, Arizona1 trial
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
Arizona Arthritis and Rheumatology Research PLLC
Phase 4
La Jolla, California1 trial
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
University of California, San Diego
San Diego, California1 trial
Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
University of California, San Diego
N/A
Loxahatchee Groves, Florida1 trial
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Family Arthritis Center
Phase 3
Atlanta, Georgia1 trial
Phase 3
Boston, Massachusetts1 trial
Multi-Center PAMPA Study
Brigham and Women's Hospital
Phase 4
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.